1378 Preclinical characterization of IMGS-001, a dual antagonist anti-PD-L1, anti-PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade
1378 Preclinical characterization of IMGS-001, a dual antagonist anti-PD-L1, anti-PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade